The Technical Analyst
Quanterix Corp [QTRX]
Exchange: NASDAQ Global Market Sector: Healthcare Industry: Medical Devices
Quanterix Corp Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
3.71% $16.79
Last updated: 3 jul 2022 - 20:35
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 619.72 mill |
| EPS: | -1.796 |
| P/E: | 0.000 |
| Earnings Date: | Aug 03, 2022 |
| SharesOutstanding: | 36.91 mill |
| Avg Daily Volume: | 0.348 mill |
| RATING 2022-07-01 |
|---|
| B+ |
| Buy |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$27.65 (64.66%) $10.86 |
| Date: 2022-07-04 |
| True Range Average |
|---|
|
+/- $1.312 ( +/- 7.81%) Range: 15.48 - 18.10 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-06-13 | Toloue Masoud | Sell | 5 564 | Common Stock |
| 2022-06-06 | Flynn Karen | Buy | 19 841 | Stock Option (right to buy) |
| 2022-06-06 | Flynn Karen | Buy | 13 227 | Common Stock |
| 2022-06-02 | Fry John J | Sell | 378 | Common Stock |
| 2022-06-02 | Hrusovsky E Kevin | Sell | 712 | Common Stock |
| INSIDER POWER |
|---|
| -0.57 |
| Last 100 transactions |
| Buy: 429 588 | Sell: 530 100 |
Forecast:
16:00 - $16.79
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $16.79
Forecast 2: 16:00 - $16.79
Forecast 3: 16:00 - $16.79
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $16.79 (3.71% ) |
| Volume | 0.160 mill |
| Avg. Vol. | 0.348 mill |
| % of Avg. Vol | 45.98 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For QTRX
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since 31-12-69
| Date | Signal | @ | Closed | % | Jun 29 - 16:20 | sell | $16.71 | N/A | Active |
|---|
QTRX
Quanterix Corp. engages in the development of ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The company is headquartered in Billerica, Massachusetts and currently employs 177 full-time employees. The firm offers single molecule array (Simoa) platform, which uses single molecule measurements to detect protein biomarkers. The firm is also focusing to enable and develop novel therapies and diagnostics to facilitate in healthcare for earlier detection, monitoring, prognosis and, ultimately, prevention of disease. Simoa focuses on research and clinical testing applications and significantly advances enzyme-linked immunosorbent assay (ELISA) technology which is capable of unprecedented protein detection sensitivity. The company also focuses on research and diagnostics for brain injuries, heart disease, cancer and other infectious diseases with its technology. The firm offers Simoa HD-1 analyzer, which is an automated immunoassay platform with multiplexing and custom assay capability.
Latest Press Releases
2022-06-06 08:36:00 - Press Release
Quanterix Announces Appointment Of Karen A. Flynn To Board Of Directors
Billerica, mass.--(business wire)--quanterix corporation (nasdaq: qtrx), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that karen a. flynn, senior vice president and chief commercial officer of catalent pharma solutions (nyse: ctlt), has been appointed to quanterix' board of directors effective june 6, 2022. ms. flynn is an accomplished healthcare leader with over 35 years of commercial, operations and general management expe
2022-04-04 16:30:00 - Press Release
Quanterix' Simoa® Technology Powers Large, International Comprehensive Reference Range Study Utilizing Serum Neurofilament Light (snfl) To Assess Disease Activity In Multiple Sclerosis (ms) Patients
Billerica, mass.--(business wire)--quanterix corporation (nasdaq: qtrx), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced its simoa® technology supported a large international and comprehensive study to establish reference ranges of snfl to assess disease activity and drug response in ms patients at the individual level, according to a recent study published in the lancet neurology. researchers from the university hospital basel
2022-03-29 16:30:00 - Press Release
Quanterix Receives Funding From The Alzheimer's Drug Discovery Foundation To Accelerate Alzheimer's Disease Diagnostic Plasma Test Development
Billerica, mass.--(business wire)--quanterix receives funding from the alzheimer's drug discovery foundation to accelerate alzheimer's disease diagnostic plasma test development
2022-03-03 16:30:00 - Press Release
Quanterix To Participate In The Cowen 42nd Annual Health Care Conference On March 9
Billerica, mass.--(business wire)--quanterix to participate in the cowen 42nd annual health care conference on march 9
2022-03-01 07:30:00 - Press Release
Quanterix Corporation Releases Operating Results For Fourth Quarter And Full Year 2021
Billerica, mass.--(business wire)--quanterix corporation (nasdaq: qtrx), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced financial results for the fourth quarter and twelve months ending december 31, 2021. “we‘ve reached an important inflection point with the achievement of several key milestones, namely, our license and collaboration agreements with eli lilly, fda breakthrough device designation for plasma ptau-181 for alzheim
Latest News
2022-06-09 16:30:00 - Business Wire
Quanterix to Participate in Goldman Sachs 43rd Annual Global Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced that its Chief Executive Officer, Masoud Toloue, will join the Goldman Sachs 43rd Annual Global Healthcare Conference for a fireside chat on June 16, 2022 at 8:40 a.m., EST. To register for the live webcast, please visit: https://kvgo.com/gs/quanterix-corp-june-2022. Toloue will also host one-on-one meetings
2022-05-10 22:34:03 - Zacks Investment Research
Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 26.87% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
2022-05-10 15:28:07 - Seeking Alpha
Quanterix Corporation (QTRX) CEO Masoud Toloue on Q1 2022 Results - Earnings Call Transcript
Quanterix Corporation (NASDAQ:QTRX ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Mike Doyle - CFO Masoud Toloue - President & CEO Conference Call Participants Max Masucci - Cowen and Company Kyle Mikson - Canaccord Matt Sykes - Goldman Sachs Puneet Souda - SVB Leerink Operator Good day, and thank you for standing by. Welcome to the Quanterix Corporation Q1 2022 Earnings Conference Call.
2022-04-27 16:50:19 - Zacks Investment Research
Quanterix Corporation (QTRX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Quanterix Corporation (QTRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
2022-03-01 14:36:09 - Seeking Alpha
Quanterix Corporation (QTRX) CEO Kevin Hrusovsky on Q4 2021 Results - Earnings Call Transcript
Quanterix Corporation (QTRX) CEO Kevin Hrusovsky on Q4 2021 Results - Earnings Call Transcript
2022-02-23 16:30:00 - Business Wire
Quanterix Corporation to Release Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation to Release Fourth Quarter and Full Year 2021 Financial Results on March 1, 2022
2022-01-06 16:30:00 - Business Wire
Quanterix to Present at 40th Annual J.P. Morgan Healthcare Conference
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix to Present at 40th Annual J.P. Morgan Healthcare Conference
2021-11-06 20:33:06 - Seeking Alpha
Quanterix Corporation (QTRX) CEO Kevin Hrusovsky on Q3 2021 Results - Earnings Call Transcript
Quanterix Corporation (QTRX) CEO Kevin Hrusovsky on Q3 2021 Results - Earnings Call Transcript
2021-10-28 16:30:00 - Business Wire
Quanterix Corporation to Release Third Quarter 2021 Financial Results on Nov. 4, 2021
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation to Release Third Quarter 2021 Financial Results on Nov. 4, 2021
2021-10-12 12:09:29 - The Motley Fool
Why Shares of Quanterix Are Climbing This Morning
